OpenNashPodcasts

Person

Vijay Pande

3 episodes · 20 quoted claims

Vijay Pande joined Andreessen Horowitz in 2015 and launched the firm's first life sciences and health care fund.

“So I came in 2015 and I launched our first life sciences and healthcare fund, first bio fund.”

NEJM AI Grand Rounds · 0:01:01

Pande was a Stanford faculty member from 1999 until he joined Andreessen Horowitz in 2015, roughly 15 to 16 years.

“Yes, I started in 99 and I started at A16Z in 2015, so 15, 16 years.”

NEJM AI Grand Rounds · 0:05:41

At Stanford, Pande was primarily in chemistry, held appointments in computer science and structural biology, and chaired biophysics.

“And I was primarily in chemistry, but had appointments in computer science, structural biology, and I was chair of biophysics.”

NEJM AI Grand Rounds · 0:05:41

Pande says Andreessen Horowitz's bio and health team is now on its fourth fund and has over 50 people.

“And so we're now on their fourth fund and now it's about over 50 people on the team.”

NEJM AI Grand Rounds · 0:01:01

Pande says a company called Genesis spun out of his Stanford lab as an example of computational drug design becoming a company.

“And even Genesis spun out of my lab is a really beautiful example of that.”

NEJM AI Grand Rounds · 0:24:29

Pande says he sits on the board of Insitro, a company led by Daphne that applies AI to drug design and human biology.

“And so InCitro is her vision for bringing AI to drug design.”

NEJM AI Grand Rounds · 0:12:01

Pande says the A16Z bio thesis rests on engineering, where steady improvement of about 20% a year compounds over decades, as with Moore's law and falling genomics costs.

“And when we talk about engineering, what we really like about engineering is the fact you can make it 20 % better year over year.”

NEJM AI Grand Rounds · 0:09:22

Pande says biotech companies reach an IPO faster than tech companies, though revenue starts later and can then ramp quickly.

“The funny thing is like the timescales for IPO for biotech is faster. The timescale to revenue is slower, but the revenue ramp can be really fast.”

NEJM AI Grand Rounds · 0:10:50

Pande cites the often-repeated statistic that curing cancer would add about three years of lifespan, to argue that care delivery matters as much as new drugs.

“The quote that's usually brought up is that even curing cancer would lead to three years of added lifespan.”

NEJM AI Grand Rounds · 0:15:36

Pande says Hippocratic AI, an A16Z-backed company, provides AI nurses and avoids diagnosing or prescribing drugs.

“So what Hippocratic does is that it provides essentially AI nurses.”

NEJM AI Grand Rounds · 0:16:22

Pande argues that spending on health care for the already sick is economically inelastic, so people will pay almost anything.

“healthcare as sick care, basically dealing with you once you're sick, that is inelastic from an economic point of view.”

NEJM AI Grand Rounds · 0:20:49

Pande describes Devoted Health as a Medicare Advantage plan that acts as both insurer and provider, giving it an incentive to avoid readmissions.

“Devoted Health, which has a Medicare Advantage plan and dual plan, but more broadly a healthcare company both as an insurance company and as a provider.”

NEJM AI Grand Rounds · 0:22:40

Pande says a well-known academic can raise a $5 million pre-seed round more easily than win a comparable grant.

“I think for someone to raise $5 million in a pre-seed round is relatively straightforward, especially someone who's well-known at the caliber of a strong academic professor.”

NEJM AI Grand Rounds · 0:25:41

Pande says he was at Stanford, chairing biophysics in the medical school, during the merger and later unmerger of the UCSF and Stanford medical systems.

“And I was at Stanford during the UCSF Stanford merger and unmerger. I was chair of biophysics then, which is in the med school.”

NEJM AI Grand Rounds · 0:29:39

Pande says his academic lineage traces back through his advisor's advisor's advisor to physicist Lev Landau.

“So my advisor's advisor advisor was Lev Landau, the storied Russian theoretical physicist and so on.”

NEJM AI Grand Rounds · 0:31:36

Pande says that at Berkeley he got fan mail meant for jazz pianist Vijay Iyer, who had held the same email address before him.

“VJ Iyer, the famous jazz pianist and pianos, my instrument too, had the email VJ at Berkeley, physical Berkeley to do right before I did.”

NEJM AI Grand Rounds · 0:33:06

Pande compares the AI market to early microprocessors, where a few players led, then many appeared, and Intel later dominated again.

“And if you remember the early days of microprocessors, there were a few like the, uh, 4004 and the 808 and then 8080”

NEJM AI Grand Rounds · 0:41:53

Pande estimates that a large share of the world's energy, perhaps 10% to 30%, should go to AI.

“And I think the answer is a relatively large fraction considering the implications of this. And so back of the envelope calculations, 10%, 20%, 30%.”

NEJM AI Grand Rounds · 0:44:33

Pande argues that the 2029 AGI forecast assumes exponential progress, whereas a sigmoid curve would level off before reaching AGI.

“And this 2029 number would be a very natural thing if the S curve were an exponential. But what if it were a sigmoid?”

NEJM AI Grand Rounds · 0:47:33

Vijay Pande notes that children generally do not take part in clinical trials and are dosed like small adults.

“certainly children generally don't go through clinical trials and we dose them like small adults for better or worse”

Raising Health (a16z) · 0:07:03